The genetics behind the progression of myelodysplasia to secondary acute myeloid leukemia (sAML) is poorly understood. In this study, we profiled somatic mutations and their dynamics using next ...

AML 作为一种侵袭性血液恶性肿瘤，具有显著的生物学和临床异质性，精准的风险分层对优化治疗效果、减少治疗相关并发症至关重要。目前，细胞遗传学变化和基因突变已被用于风险分层，其中 NPM1 和 FLT3-ITD 是 AML 患者中最常见的复发性基因突变 。然而，对这些突变进行分子检测存在诸多挑战，如不同机构资源和实验室基础设施差异大，限制了检测的可及性，延长了检测周转时间。

Recent progress in the molecular genetics of acute myeloid leukemia (AML) has shown this disease to be more heterogeneous than previously realized. Recurrent cytogenetic and mutational changes in ...

studied hundreds of patients with acute myeloid leukemia (AML). They discovered that specific mutations in the STAG2 protein ...

Aptose Biosciences (NASDAQ:APTO;TSX:APS), a clinical-stage oncology stock, achieved positive safety and response results from ...

A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled “A case report of donor cell–derived ...

In January 2025, Aptose announced the initiation of the TUSCANY trial and dosing in the first cohort of newly-diagnosed AML patients with the lowest starting dose (40 mg) of TUS as part of the ...

Around one-third of patients with acute myeloid leukemia (AML) harbor FLT3 gene mutations which are associated with poor prognosis and high risk of relapse. Several compounds targeting FLT3 internal ...

Kuro Oncology and partner Kyowa Kirin are on track for an NDA submission for ziftomenib in the second quarter of this year.

Current efforts in the laboratory focus on other aspects of how cells that acquire p53 mutations evolve towards cancer. Complex Karyotype Acute Myeloid Leukemia as a Paradigm of a p53 Mutant Cancer ...